Natera, Inc. (NTRA) KPIs and segments
Close on Nov 18, 2026Market cap $41.73BP/E –Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Natera · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
Nhìn nhanh KPI của Natera: 31 chỉ số vận hành, trong đó có Total Tests Processed, Total Consolidated Revenue và U.S. Direct Sales Force Revenue Share, lấy từ 170 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product revenues($M) | 748 | 694 | 661 | 590 | 544 | 500 | 473 | 436 | 411 | 365 | 307 | 265 | |
Licensing and other revenues($M) | 4.82 | 2.78 | 4.34 | 1.99 | 2.17 | 1.79 | 3.15 | 3.63 | 1.99 | 3.07 | 3.85 | 3.09 | |
United States($M) | 739 | 686 | 652 | 582 | 538 | 492 | 467 | 426 | 405 | 359 | 301 | 260 | |
Europe, Middle East, India, Africa($M) | 9.02 | 6.43 | 6.01 | 5.41 | 6.05 | 7.72 | 5.44 | 5.18 | 5.26 | ||||
Americas, excluding U.S.($M) | 2.22 | 2.40 | 4.57 | 1.52 | 1.57 | 1.69 | 1.54 | 2.00 | 1.60 | 1.48 | 1.26 | 1.29 | |
Asia Pacific and Other($M) | 2.05 | 2.22 | 2.13 | 2.28 | 1.82 | 1.78 | 1.79 | 3.76 | 1.44 | 1.67 | 1.89 | 1.89 | |
Product revenues($M) | 481 | 449 | 442 | 383 | 345 | 315 | 297 | 268 | 242 | 206 | 156 | 118 | |
Licensing and other revenues($M) | 3.86 | 2.17 | 3.50 | 1.44 | 1.71 | 1.34 | 2.69 | 3.28 | 1.66 | 2.76 | 3.65 | 2.74 | |
Total Tests Processed — Lab + Constellation Platform (tests)3 | 1,043,900.00 | 1,013,600.00 | 923,600.00 | 893,600.00 | 853,100.00 | 855,100.00 | 792,800.00 | 775,800.00 | 760,300.00 | 735,800.00 | 626,800.00 | 626,000.00 | |
Tests Accessioned in Natera's CLIA Laboratories (tests) | 1,030,100.00 | 999,200.00 | 909,000.00 | 879,700.00 | 839,300.00 | 840,800.00 | 778,400.00 | 760,700.00 | 744,000.00 | 718,700.00 | 610,100.00 | 609,800.00 | |
Total Tests Reported — Resulting in a Customer Report (tests)1 | 985,500.00 | 931,600.00 | 892,400.00 | 832,900.00 | 812,900.00 | 804,800.00 | 771,700.00 | 750,100.00 | 725,200.00 | 679,400.00 | 619,800.00 | 590,000.00 | |
Tests Reported in Natera's CLIA Laboratories (tests) | 972,000.00 | 918,100.00 | 878,000.00 | 819,900.00 | 799,900.00 | 791,400.00 | 758,200.00 | 735,900.00 | 709,800.00 | 663,500.00 | 604,200.00 | 575,000.00 | |
Total Oncology Tests Processed — Signatera MRD + Altera + Research (tests)2 | 296,700.00 | 258,900.00 | 233,300.00 | 211,000.00 | 188,800.00 | 167,700.00 | 150,800.00 | 137,100.00 | 125,400.00 | 114,800.00 | 97,500.00 | 88,800.00 | |
Clinical MRD Oncology Tests Processed — Quarterly (thousand tests) | 283.00 | 249.00 | 225.00 | 202.00 | 181.00 | 161.00 | 145.00 | 130.00 | 118.00 | 106.00 | 91.00 | 81.00 | |
Signatera Clinical Average Selling Price — Realized ASP ($/test)($) | 1,275 | 1,250 | 1,225 | 1,200 | 1,175 | ||||||||
Total Consolidated Revenue — Disaggregated by Payer & Product ($M)($M)3 | 753 | 697 | 666 | 592 | 547 | 502 | 476 | 440 | 413 | 368 | 311 | 268 | |
Insurance Carriers Revenue — Third-Party Commercial & Government Payers ($M)($M) | 705 | 658 | 622 | 560 | 517 | 473 | 441 | 405 | 384 | 341 | 277 | 240 | |
Laboratory Partners & Hospitals Revenue — Institutional Payers ($M)($M) | 37.7 | 28.8 | 35.0 | 25.1 | 22.2 | 20.8 | 27.1 | 27.6 | 22.3 | 20.3 | 26.9 | 21.7 | |
Patients Revenue — Self-Pay & Out-of-Pocket Co-Pays ($M)($M) | 9.92 | 9.74 | 8.43 | 7.58 | 7.44 | 8.35 | 7.55 | 6.93 | 6.97 | 6.44 | 6.72 | 6.79 | |
U.S. Direct Sales Force Revenue Share (%)(%)1 | 96.0% | 94.0% | |||||||||||
U.S. Laboratory Partners Revenue Share (%)(%) | 2.0% | 5.0% | |||||||||||
Revenue Recognized from Prior-Period Completed Tests — Cash Collection True-Ups ($M)($M)2 | 52.3 | 61 | 59.7 | 55.1 | 45.3 | 34.3 | 43.1 | 34.5 | 39.9 | 33.7 | 9 | 2.20 | |
Diluted EPS Impact of Prior-Period Revenue True-Ups ($/sh)($) | 0.36 | 0.43 | 0.40 | 0.33 | 0.25 | 0.28 | 0.32 | 0.28 | 0.02 | ||||
Revenue Offset for Prior-Period Insurance Non-Refunded Considerations ($M) [legacy through Q3 2025]($M) | 0.20 | 0.40 | 3.50 | -0.20 | 0.40 | 0.60 | -1.50 | ||||||
GAAP Gross Profit ($M)($M)1 | 485 | 451 | 445 | 384 | 347 | 317 | 300 | 272 | 243 | 209 | 160 | 121 | |
GAAP Gross Margin (%)(%) | 64.5% | 64.7% | 66.9% | 64.9% | 63.4% | 63.1% | 62.9% | 61.8% | 58.8% | 56.7% | 51.4% | 45.1% | |
Total Contract Liabilities — Deferred Revenue ($M)($M)10 | 56.6 | 53.9 | 42.0 | 38.2 | 38.1 | 37.3 | 36.6 | 34.8 | 36.8 | 36.5 | 35.7 | 36.1 | |
Deferred Revenue, Current ($M)($M) | 40.6 | 36.9 | 24.9 | 21.8 | 21.6 | 20.6 | 19.8 | 17.9 | 18.4 | 17.7 | 16.6 | 15.0 | |
Deferred Revenue, Long-Term / Noncurrent ($M)($M) | 16.1 | 17 | 17.1 | 16.4 | 16.5 | 16.7 | 16.8 | 16.9 | 18.4 | 18.8 | 19.1 | 21.0 | |
Contract Liability Roll-Forward: Additions / Deferrals in Period ($M)($M) | 26.4 | 28.4 | 19.6 | 10.5 | 10.2 | 10.2 | 11.5 | 9.14 | 6.89 | 7.94 | 11.0 | 7.15 | |
Contract Liability Roll-Forward: Revenue Recognized from Beginning Balance ($M)($M) | -11.8 | -11.3 | -2.80 | -1.50 | -5.48 | -9.42 | -1.59 | -2.45 | -2.60 | -7.05 | -0.95 | -2.09 | |
Contract Liability Roll-Forward: Revenue Recognized from Same-Period Deferrals ($M)($M) | -11.8 | -5.23 | -13.1 | -8.79 | -3.93 | -0.07 | -8.09 | -8.66 | -4.04 | -0.10 | -9.84 | -6.17 | |
BGI Genomics License Agreement — Current Contract Liability ($M) [legacy through Q3 2025]($M) | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 1.20 | 1.20 | |||||
BGI Genomics License Agreement — Noncurrent Contract Liability ($M) [legacy through Q3 2025]($M) | 16.4 | 16.5 | 16.7 | 16.8 | 16.9 | 18.4 | 17.3 | 17.6 | 19.3 | ||||
Foundation Medicine Collaboration — Current Contract Liability ($M) [legacy through Q3 2025]($M) | 1.70 | 1.70 | 1.50 | 1.70 | 3 | 3 | 1.60 | 1.70 | 2.20 | ||||
Genetic Testing Services — Current Contract Liability ($M) [legacy through Q3 2025]($M) | 19.6 | 19.4 | 18.6 | 14.4 | 14.8 | 14.9 | 13.7 | 12.8 | |||||
BGI Genomics Remaining Performance Obligations — RPO ($M) [legacy through Q1 2025]($M) | 6 | 20 | 6 | 6 | 6 | ||||||||
Total Unconditional Purchase Obligations ($M)($M)6 | 221 | 261 | 257 | 158 | 177 | 169 | 171 | 101 | 104 | 92.4 | 94.5 | 64.6 | |
Inventory & Laboratory Sequencing Materials Purchase Obligations ($M)($M) | 120 | 136 | 107 | 61.5 | 80.8 | 70.4 | 54.0 | 34.4 | 35.6 | 24.6 | 20.7 | 23.3 | |
Other Material Supplier Purchase Obligations ($M)($M) | 48.3 | 72.4 | 89.1 | 39.8 | 39.3 | 44.6 | 51.2 | 25.7 | 22.3 | 16.9 | 11.9 | 14.7 | |
Application & IT Enterprise Services Purchase Obligations ($M)($M) | 15.9 | 16.4 | 13.6 | 7.33 | 5.68 | 4.73 | 4.23 | 3.90 | 4.19 | 4.51 | 12.6 | 14.6 | |
Laboratory Sequencing Instruments & Equipment Purchase Obligations ($M)($M) | 13.4 | 16.2 | 18.9 | 21.2 | 23.5 | 21.4 | 27.7 | 2.24 | 4.40 | 7.62 | 9.40 | 9.40 | |
Cloud Computing & Bioinformatics Infrastructure Purchase Obligations ($M)($M) | 22.7 | 20.2 | 28.0 | 28.4 | 27.4 | 27.4 | 34.2 | 34.2 | 36.6 | 38.4 | 40 | ||
Clinical Trial Samples & Registry Study Purchase Obligations ($M)($M) | 1.30 | 1.30 | 1.30 | 6 | 6 | 6 | 13 | ||||||
Property and Equipment, Gross ($M)($M)8 | 451 | 390 | 352 | 307 | 281 | 267 | 240 | 213 | 198 | 185 | 168 | 155 | |
Machinery and Laboratory Sequencing Equipment, Gross ($M)($M) | 215 | 183 | 171 | 153 | 140 | 129 | 117 | 104 | 94.8 | 90.7 | 85.6 | 83.5 | |
Laboratory & Facility Leasehold Improvements, Gross ($M)($M) | 76.8 | 62.5 | 62.2 | 49.2 | 49.2 | 48.9 | 48.6 | 48.1 | 47.7 | 47.5 | 39 | 39 | |
Construction in Progress — Lab Expansion & Automation ($M)($M) | 131 | 120 | 94.0 | 83.7 | 73.7 | 71.3 | 58.5 | 46.6 | 41.6 | 33.2 | 29.4 | 20.8 | |
Capitalized Internal-Use Software, Gross ($M)($M)1 | 21.6 | 20.1 | 21.2 | 17.6 | 14.9 | 14.6 | 13.2 | 11.1 | 10.7 | 11.1 | 11.6 | 10.3 | |
Capitalized Internal-Use Software, Net Carrying Value ($M)($M) | 31.2 | 3.50 | 2.40 | ||||||||||
Computer & Bioinformatics Hardware Equipment, Gross ($M)($M) | 5.38 | 3.99 | 3.63 | 3.44 | 3.34 | 3.29 | 3.18 | 3.04 | 3.04 | 2 | 1.85 | 1.81 | |
Less: Accumulated Depreciation and Amortization ($M)($M) | 133 | 120 | 111 | 101 | 91.7 | 86.6 | 78.4 | 71.1 | 64.5 | 58.7 | 56.3 | 50.6 | |
Property and Equipment, Net ($M)($M) | 318 | 269 | 241 | 207 | 189 | 180 | 162 | 142 | 133 | 126 | 111 | 105 | |
Depreciation Expense on Property and Equipment ($M)($M) | 13.1 | 12.6 | 10.1 | 9.30 | 8.90 | 8.20 | 7.30 | 6.60 | 7 | 6.30 | 6.60 | 5.90 | |
Acquired Finite-Lived Intangible Assets, Gross ($M)($M)3 | 379 | 379 | 379 | 11.9 | |||||||||
Less: Accumulated Amortization of Intangible Assets ($M)($M) | 19.2 | 12.0 | 4.88 | 0.96 | |||||||||
Acquired Finite-Lived Intangible Assets, Net ($M)($M) | 360 | 367 | 374 | 10.9 | |||||||||
Foresight Diagnostics Acquisition Contingent Consideration Liability — Total Fair Value ($M)($M)2 | 121 | 126 | 118 | ||||||||||
Foresight Contingent Consideration — Current Liability ($M)($M) | 22.8 | 22.4 | 21.6 | ||||||||||
Foresight Contingent Consideration — Noncurrent Liability ($M)($M) | 97.7 | 103 | 96.8 | ||||||||||
Total Operating Lease Liabilities ($M)($M)8 | 158 | 160 | 134 | 118 | 116 | 115 | 107 | 109 | 73.6 | 76.1 | 78.7 | 79.3 | |
Operating Lease Right-of-Use (ROU) Assets ($M)($M) | 130 | 134 | 109 | 97.0 | 95.1 | 94.6 | 86.2 | 87.9 | 52.6 | 54.6 | 56.5 | 58.2 | |
Operating Lease Liabilities, Current ($M)($M) | 15.1 | 14.8 | 15.6 | 14.0 | 13.1 | 12.2 | 10.2 | 9.76 | 12.4 | 12.0 | 11.6 | 11.0 | |
Operating Lease Liabilities, Noncurrent ($M)($M) | 143 | 145 | 118 | 104 | 103 | 103 | 96.6 | 99.0 | 61.2 | 64.2 | 67.0 | 68.3 | |
Operating Lease Cost ($M)($M) | 7.42 | 5.93 | 5.45 | 5.40 | 4.96 | 4.39 | 4.15 | 3.97 | 3.61 | 3.59 | 3.51 | 3.56 | |
Operating Cash Outflows for Operating Leases ($M)($M) | 6.10 | 5.90 | 5.60 | 4.90 | 4.80 | 4.50 | 4.30 | 4.20 | 4.10 | 4.10 | 4 | 3.20 | |
Weighted-Average Remaining Lease Term — Operating Leases (years)(năm) | 7.0 | 7.2 | 6.9 | 6.9 | 7.1 | 7.4 | 7.8 | 8.0 | 6.3 | 6.5 | 6.7 | 6.9 | |
Weighted-Average Discount Rate — Operating Leases (%)(%) | 6.6% | 6.5% | 6.8% | 7.0% | 7.1% | 7.1% | 7.2% | 7.2% | 6.8% | 6.8% | 6.8% | 6.7% | |
Total Undiscounted Future Operating Lease Payments ($M)($M)7 | 201 | 204 | 170 | 151 | 149 | 149 | 141 | 144 | 92 | 95.7 | 99.5 | 101 | |
Lease Maturity: Next Fiscal Year / Year 1 ($M)($M) | 25.1 | 24.6 | 24.3 | 22.2 | 21.1 | 20.3 | 17.5 | 17.4 | 17.2 | 17.0 | 16.6 | 16.0 | |
Lease Maturity: Year 2 ($M)($M) | 28.0 | 27.5 | 24.2 | 21.6 | 20.5 | 19.7 | 17.8 | 17.7 | 17.5 | 17.3 | 16.9 | 16.4 | |
Lease Maturity: Year 3 ($M)($M) | 28.1 | 27.6 | 24.1 | 21.5 | 20.4 | 19.8 | 17.1 | 17 | 14.3 | 14.3 | 17.3 | 16.7 | |
Lease Maturity: Year 4 ($M)($M) | 28.6 | 28.0 | 22.8 | 19.8 | 18.8 | 18.3 | 17.4 | 17.3 | 6.67 | 6.63 | 14.2 | 13.7 | |
Lease Maturity: Year 5 ($M)($M) | 23.1 | 17.3 | 6.59 | ||||||||||
Lease Maturity: Thereafter / After Year 5 ($M)($M) | 51.0 | 53.3 | 27.9 | ||||||||||
Less: Imputed Lease Interest ($M)($M) | 42.7 | 44.7 | 35.5 | 32.2 | 32.8 | 34.2 | 33.8 | 35.7 | 18.4 | 19.6 | 20.8 | 21.5 | |
Unvested Restricted Stock Units (RSUs & PSUs) Outstanding (thousand shares)4 | 7,321.00 | 7,949.00 | 8,323.00 | 8,893.00 | 9,498.00 | 9,974.00 | 11.00 | 10,856.00 | 11,338.00 | 11,901.00 | 9.00 | 9,440.00 | |
Unvested RSUs Weighted-Average Grant-Date Fair Value ($/sh)($) | 134 | 128 | 100 | 94.92 | 90.89 | 86.75 | 61.28 | 57.91 | 56.59 | 56.16 | 49.50 | 50.28 | |
RSUs & Performance Units Granted in Period (thousand shares) | 168.00 | 2,457.00 | -3,276.00 | 271.00 | 288.00 | 2,721.00 | -5,038.00 | 257.00 | 178.00 | 4,608.00 | -5,722.00 | 262.00 | |
RSUs & Performance Units Vested in Period (thousand shares) | 701.00 | 2,686.00 | -4,632.00 | 711.00 | 690.00 | 3,236.00 | -2,964.00 | 525.00 | 582.00 | 1,861.00 | -2,361.00 | 340.00 | |
RSUs & Performance Units Forfeited/Canceled in Period (thousand shares) | 95.00 | 145.00 | -342.00 | 165.00 | 74.00 | 104.00 | -466.00 | 214.00 | 159.00 | 94.00 | -759.00 | 140.00 | |
Stock Options Outstanding (thousand shares)2 | 3,132.00 | 3,242.00 | 3,591.00 | 3,739.00 | 3,804.00 | 3,822.00 | 3,875.00 | 4,176.00 | 4,423.00 | 4,709.00 | 5,501.00 | 5,532.00 | |
Stock Options Outstanding — Weighted-Average Exercise Price ($/sh)($) | 29.28 | 28.77 | 27.03 | 30.55 | 30.54 | 30.47 | 30.22 | 28.67 | 27.45 | 26.25 | 23.65 | 23.57 | |
Stock Options Outstanding — Aggregate Intrinsic Value ($M)($M) | 725 | 496 | 231 | 143 | |||||||||
Performance-Based Stock Award Compensation Expense ($M)($M)2 | 24.5 | 21.9 | 75.1 | 25.5 | 29.8 | 18.7 | 23.3 | 74 | 48.5 | 20.7 | 13.7 | 23 | |
Unrecognized Stock-Based Compensation Expense — RSUs & Options ($M)($M) | 637 | 509 | 332 | 368 | |||||||||
Weighted-Average Remaining Recognition Period for Unrecognized SBC (years)(năm) | 1.6 | 1.6 | 2.4 | 2.5 | |||||||||
Antidilutive Securities Excluded from Diluted EPS: RSUs & Performance Awards (thousand shares)2 | 7,321.00 | 7,949.00 | 8,323.00 | 8,893.00 | 9,498.00 | 9,974.00 | 10,593.00 | 10,856.00 | 11,338.00 | 11,901.00 | 9,248.00 | 9,440.00 | |
Antidilutive Securities Excluded from Diluted EPS: Stock Options (thousand shares) | 3,132.00 | 3,242.00 | 3,591.00 | 3,739.00 | 3,804.00 | 3,822.00 | 3,875.00 | 4,176.00 | 4,423.00 | 4,709.00 | 5,501.00 | 5,532.00 | |
Antidilutive Securities Excluded from Diluted EPS: ESPP Shares (thousand shares) | 29.00 | 79.00 | 34.00 | 88.00 | 39.00 | 98.00 | 40.00 | 93.00 | 41.00 | 221.00 | 88.00 | 188.00 | |
Census QSS Quarterly Revenue: U.S. Medical & Diagnostic Laboratories — NAICS 6215 ($M)($M)5 | 20,528 | 19,569 | 19,997 | 19,677 | 19,718 | 18,722 | 19,104 | 18,893 | 18,483 | 17,963 | 17,943 | 17,348 | |
Census QSS Quarterly Revenue: Ambulatory Health Care Services — NAICS 621 ($M)($M) | 414,886 | 395,174 | 407,176 | 398,164 | 389,960 | 373,423 | 380,950 | 366,854 | 362,208 | 347,178 | 347,128 | 331,113 | |
Census QSS Quarterly Revenue: Outpatient Care Centers — NAICS 6214 ($M)($M) | 45,108 | 44,022 | 45,300 | 42,797 | 41,832 | 40,030 | 40,602 | 37,897 | 37,227 | 36,087 | 37,030 | 33,974 | |
Census QSS Quarterly Revenue: Hospitals — NAICS 622 ($M)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | 41,441 | |
BEA Personal Consumption Expenditures: Health Care Services — SAAR ($B) | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.90 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | 3,079.00 | |
BEA Real PCE Quantity Index: Health Care Services (2017=100) | 135.90 | 133.62 | 133.63 | 132.73 | 130.45 | 129.02 | 127.88 | 126.71 | 124.83 | 123.75 | 121.53 | 119.23 | |
Exact Sciences Corp. (EXAS) — GAAP Revenue ($M)15 | |||||||||||||
Guardant Health, Inc. (GH) — GAAP Revenue ($M)($M) | 335 | 302 | 281 | 265 | 232 | 203 | 202 | 191 | 177 | 168 | 155 | 143 | |
Guardant Health, Inc. (GH) — GAAP Operating Income / Loss ($M)($M) | -129 | -121 | -121 | -99 | -106 | -111 | -126 | -117 | -101 | -100 | -198 | -114 | |
Myriad Genetics, Inc. (MYGN) — GAAP Revenue ($M)($M) | 191 | 200 | 210 | 206 | 213 | 196 | 211 | 213 | 212 | 202 | 197 | 192 | |
Myriad Genetics, Inc. (MYGN) — GAAP Operating Income / Loss ($M)($M) | -39 | -31 | -6 | -23 | -329 | -29 | -39 | -20 | -36 | -28 | -31 | -60 | |
Veracyte, Inc. (VCYT) — GAAP Revenue ($M)($M) | 150 | 139 | 141 | 132 | 130 | 114 | 119 | 116 | 114 | 97 | 98 | 90 | |
Veracyte, Inc. (VCYT) — GAAP Operating Income / Loss ($M)($M) | 23 | 23 | 37 | 23 | -5 | 3 | 4 | 12 | 5 | -5 | -36 | -32 | |
CareDx, Inc. (CDNA) — GAAP Revenue ($M)($M) | 132 | 118 | 108 | 100 | 87 | 85 | 87 | 83 | 92 | 72 | 66 | 67 | |
CareDx, Inc. (CDNA) — GAAP Operating Income / Loss ($M)($M) | 113 | 1 | -6 | 0 | -11 | -13 | 84 | -14 | -7 | -23 | -123 | -29 | |
NeoGenomics, Inc. (NEO) — GAAP Operating Income / Loss ($M)($M) | -10 | -18 | -13 | -27 | -48 | -28 | -18 | -21 | -22 | -31 | -19 | -24 | |
Illumina, Inc. (ILMN) — Next-Gen Sequencing Supplier GAAP Revenue ($M)($M) | 1,159 | 1,091 | 1,159 | 1,084 | 1,059 | 1,041 | 1,104 | 1,080 | 1,112 | 1,076 | 1,119 | 1,176 | |
Illumina, Inc. (ILMN) — GAAP Operating Income / Loss ($M)($M) | 245 | 209 | 201 | 227 | 214 | 164 | 175 | 741 | -1,637 | -111 | -754 | -88 | |
Quest Diagnostics Inc. (DGX) — Clinical Lab Peer GAAP Revenue ($M)($M) | 3,043 | 2,895 | 2,806 | 2,816 | 2,761 | 2,652 | 2,621 | 2,488 | 2,397 | 2,366 | 2,288 | 2,295 | |
Quest Diagnostics Inc. (DGX) — GAAP Operating Income ($M)($M) | 459 | 399 | 386 | 386 | 438 | 346 | 361 | 330 | 355 | 300 | 267 | 342 | |
Labcorp Holdings Inc. (LH) — Clinical Lab Peer GAAP Revenue ($M)($M) | 3,731 | 3,538 | 3,516 | 3,564 | 3,527 | 3,345 | 3,329 | 3,282 | 3,221 | 3,177 | 3,033 | 3,057 | |
Labcorp Holdings Inc. (LH) — GAAP Operating Income ($M)($M) | 452 | 381 | 268 | 397 | 394 | 326 | 216 | 254 | 295 | 321 | -123 | 252 | |
Revenue by Offering Type — Product vs. Licensing and Other ($M, DB)($M)2 | 753 | 697 | 666 | 592 | 547 | 502 | 476 | 440 | 413 | 368 | 311 | 268 | |
Cost of Product Revenues ($M)($M) | 267 | 245 | 219 | 207 | 200 | 185 | 176 | 168 | 170 | 159 | 151 | 147 | |
Cost of Licensing and Other Revenues ($M)($M) | 1 | 0.60 | 0.80 | 0.50 | 0.50 | 0.50 | 0.50 | 0.40 | 0.30 | 0.30 | 0.20 | 0.30 | |
Income Statement — Total Consolidated Revenue ($M, DB)($M)12 | 753 | 697 | 666 | 592 | 547 | 502 | 476 | 440 | 413 | 368 | 311 | 268 | |
Research and development expense ($M)($M) | 228 | 211 | 175 | 173 | 146 | 129 | 130 | 96.9 | 89.1 | 88.6 | 83 | 77.2 | |
Selling, general and administrative expense ($M)($M) | 327 | 328 | 291 | 309 | 311 | 267 | 235 | 214 | 198 | 194 | 161 | 155 | |
Total operating costs and expenses ($M)($M) | 829 | 790 | 688 | 690 | 657 | 581 | 541 | 479 | 457 | 442 | 396 | 379 | |
Operating income / loss ($M)($M) | -75.8 | -93.5 | -22.8 | -97.6 | -110 | -79.2 | -64.7 | -39.3 | -43.9 | -74.3 | -84.5 | -111 | |
Interest expense ($M)($M) | 0.89 | 0.89 | 0.99 | 1.04 | 1.03 | 1 | 1.29 | 3.14 | 3.13 | 3.12 | 3.15 | 3.25 | |
Income / loss before income taxes ($M)($M) | -67.2 | -84.8 | -13.3 | -87.3 | -101 | -66.8 | -55.1 | -30.9 | -36.6 | -67.2 | -77.8 | -109 | |
Income tax expense / benefit ($M)($M) | -0.26 | 0.28 | -60.6 | 0.21 | 0.27 | 0.17 | -1.35 | 0.73 | 0.89 | 0.43 | 0.19 | 0.20 | |
Net income / loss ($M)($M) | -67 | -85.1 | 47.3 | -87.5 | -101 | -66.9 | -53.8 | -31.6 | -37.5 | -67.6 | -78 | -109 | |
Net income / loss per share — Basic ($/sh)($) | -0.47 | -0.60 | -0.64 | -0.74 | -0.50 | -0.26 | -0.30 | -0.56 | -0.95 | ||||
Net income / loss per share — Diluted ($/sh)($) | -0.47 | -0.60 | -0.64 | -0.74 | -0.50 | -0.26 | -0.30 | -0.56 | -0.95 | ||||
Weighted-average basic shares outstanding (M) | 143.30 | 141.50 | 137.20 | 136.40 | 134.80 | 123.80 | 122.90 | 120.80 | 115.20 | ||||
Weighted-average diluted shares outstanding (M) | 143.30 | 141.50 | 137.20 | 136.40 | 134.80 | 123.80 | 122.90 | 120.80 | 115.20 | ||||
Balance Sheet — Total Assets ($M, DB)($M)18 | 2,658 | 2,614 | 2,398 | 1,822 | 1,757 | 1,732 | 1,661 | 1,591 | 1,517 | 1,468 | 1,442 | 1,447 | |
Cash and cash equivalents ($M)($M) | 1,092 | 1,088 | 1,076 | 1,041 | 1,000 | 974 | 946 | 893 | 797 | 814 | 642 | 669 | |
Accounts receivable, net ($M)($M) | 422 | 418 | 297 | 286 | 309 | 318 | 314 | 307 | 336 | 289 | 278 | 255 | |
Inventory ($M)($M) | 80.3 | 70.7 | 68.4 | 64.6 | 54.3 | 50.4 | 44.7 | 48.7 | 41 | 43 | 40.8 | 42.1 | |
Prepaid expenses and other current assets ($M)($M) | 65.1 | 75.6 | 55.8 | 53.9 | 52.1 | 56.2 | 48.6 | 44.6 | 37.8 | 46.7 | 60.5 | 33.5 | |
Total current assets ($M)($M) | 1,659 | 1,652 | 1,497 | 1,447 | 1,432 | 1,416 | 1,376 | 1,323 | 1,302 | 1,261 | 1,259 | 1,267 | |
Property and equipment, net ($M)($M) | 318 | 269 | 241 | 207 | 189 | 181 | 162 | 142 | 133 | 126 | 111 | 105 | |
Operating lease right-of-use assets ($M)($M) | 130 | 134 | 109 | 97 | 95.1 | 94.6 | 86.1 | 87.9 | 52.6 | 54.6 | 56.5 | 58.2 | |
Goodwill ($M)($M) | 141 | 141 | 141 | ||||||||||
Intangible assets, net ($M)($M) | 360 | 367 | 374 | 10.9 | |||||||||
Other long-term assets ($M)($M) | 50 | 51 | 36.9 | 70.7 | 41.1 | 40.9 | 25.8 | 38.4 | 29.3 | 26.4 | 15.4 | 16.2 | |
Accounts payable ($M)($M) | 75.2 | 62.4 | 33.2 | 46.5 | 36.9 | 39.2 | 34.9 | 27.8 | 33.1 | 26 | 15 | 21.3 | |
Accrued expenses and other current liabilities ($M)($M) | 229 | 213 | 189 | 216 | 191 | 178 | 147 | 126 | 141 | 142 | 149 | 134 | |
Deferred revenue, current ($M)($M) | 40.6 | 36.9 | 24.9 | 21.8 | 21.6 | 20.6 | 19.8 | 17.9 | 18.4 | 17.7 | 16.6 | 15 | |
Total current liabilities ($M)($M) | 553 | 558 | 441 | 442 | 385 | 366 | 344 | 301 | 315 | 306 | 307 | 290 | |
Total liabilities ($M)($M) | 836 | 840 | 686 | 569 | 511 | 493 | 465 | 712 | 681 | 674 | 676 | 662 | |
Additional paid-in capital ($M)($M) | 4,750 | 4,635 | 4,489 | 4,076 | 3,982 | 3,875 | 3,764 | 3,393 | 3,320 | 3,241 | 3,146 | 3,089 | |
Accumulated deficit / retained earnings ($M)($M) | -2,928 | -2,861 | -2,776 | -2,823 | -2,736 | -2,635 | -2,568 | -2,514 | -2,483 | -2,445 | -2,377 | -2,299 | |
Total stockholders' equity ($M)($M) | 1,822 | 1,774 | 1,712 | 1,252 | 1,246 | 1,240 | 1,195 | 879 | 837 | 794 | 765 | 785 | |
Cash Flow Statement — Operating Cash Flow ($M, DB)($M)6 | 54.8 | 40.2 | 73.9 | 59.4 | 37.6 | 44.5 | 52.9 | 51.8 | 4 | 27 | -57.6 | -29.7 | |
Stock-based compensation ($M)($M) | 103 | 95.1 | 92.6 | 90.6 | 93.4 | 77.8 | 71.9 | 70.6 | 67.4 | 64.4 | 49.4 | 57.6 | |
Depreciation and amortization ($M)($M) | 15.5 | 14.5 | 12.4 | 10.3 | 9.90 | 9.20 | 7.80 | 8.20 | 7.90 | 7.10 | 6.90 | 7 | |
Purchases of property and equipment — CapEx ($M)($M) | 63.4 | 22.1 | 36.1 | 22.4 | 25.9 | 21.8 | 18.1 | 16.3 | 11.7 | 20.3 | 10.1 | 9 | |
Net cash used in investing activities ($M)($M) | -63.4 | -32.1 | -71.6 | -19.9 | -23.9 | -16.8 | -11.1 | 42.5 | -32.1 | 138 | 24.1 | 81.3 | |
Net cash provided by financing activities ($M)($M) | 12.2 | 3.80 | 32.4 | 1.90 | 12.6 | 0.50 | 11 | 1.70 | 11 | 6.50 | 6.80 | 236 | |
Cash paid for interest ($M)($M) | 0.89 | 0.89 | 0.99 | 1.04 | 1.03 | 1 | 1.11 | 1.19 | 4.41 | 1.18 | 4.44 | 1.31 | |
14 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar & single reportable segment: Natera, Inc. (NASDAQ: NTRA, CIK 0001604821) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Natera manages its cell-free DNA (cfDNA) molecular diagnostics business as a single reportable operating segment across three primary clinical franchises: Women's Health (Panorama NIPT, Horizon Carrier Screening, Vistara, Spectrum, Empower, Anora), Oncology (Signatera personalized ctDNA minimal residual disease [MRD] test and Altera comprehensive genomic profiling), and Organ Health (Prospera transplant rejection assessment and Renasight kidney gene panel).
- Core operational & diagnostic volume KPIs (Groups 1–2) cover: (1) Total Tests Processed (985,600 in Q2 2026 / 3,522,000 in FY2025 across 35 quarters 2017Q1–2026Q2 and 10 years FY2015–FY2025), Tests Accessioned in Natera's CLIA Laboratories (966,600 in Q2 2026 / 3,453,100 in FY2025), Total Tests Reported (3,290,000 in FY2025), Total Oncology Tests Processed (242,800 in Q2 2026 / 814,200 in FY2025), Clinical MRD Oncology Tests Processed (228.5 thousand in Q2 2026 / 769,700 exact clinical tests in FY2025), and Signatera Realized ASP (~$1,300/test in Q2 2026 up from ~$1,165/test in Q2 2025); and (2) Revenue Disaggregated by Payer Type across 38 quarters (Insurance Carriers $705.09M [93.7%], Laboratory Partners $37.74M [5.0%], Patients $9.92M [1.3%] in Q2 2026), Legacy Product Revenue Disaggregation (Panorama NIPT, Horizon HCS, Other Genetic Tests, Constellation, Other Licensing through 2020Q1), Sales Channel Mix (97% U.S. Direct Sales Force in FY2025), Prior-Period Cash Collection Revenue True-Ups ($52.3M or $0.36/sh diluted EPS impact in Q2 2026; $161.3M or $1.18/sh in FY2025), and GAAP Gross Profit ($498.4M / 66.2% gross margin in Q2 2026; $1,481.2M / 64.1% in FY2025).
- Contract liabilities, purchase obligations, laboratory infrastructure & governance (Groups 3–6) cover: (3) Contract Liabilities ($64.25M total at Q2 2026 across $31.73M current and $32.52M noncurrent) with complete quarterly roll-forward (additions, revenue recognized from beginning balance, and same-period deferrals) and BGI Genomics / Foundation Medicine / Qiagen collaboration balances; (4) Unconditional Purchase Obligations ($189.20M total at Q2 2026 across $87.90M inventory & sequencing consumables, $39.56M other material suppliers, $36.13M application & IT services, $17.87M laboratory instruments, $6.47M cloud computing, and $1.27M clinical trial samples); (5) CLIA Laboratory Facilities (520,256 sq ft total in FY2025 across San Carlos, CA 136,000 sq ft, Austin, TX 225,847 sq ft, and South San Francisco, CA 88,974 sq ft), Property & Equipment ($256.83M gross / $143.93M net at Q2 2026 including $147.82M machinery & lab sequencers and $67.74M leasehold improvements), Foresight Diagnostics acquisition contingent consideration liability ($98.06M fair value at Q2 2026), and Operating Lease Maturity Schedule ($93.31M lease liabilities / $126.90M undiscounted payments at Q2 2026); and (6) Equity Awards (5,637K unvested RSUs at $115.65 WAGDFV and 3,591K options at $30.22 WAEP), Antidilutive Securities, and DEF 14A CEO/NEO Pay-Versus-Performance & CEO Pay Ratio (111x in FY2025).
- Workforce, safety, environmental sustainability & benchmarks (Groups 7–9) cover: (7) Global Workforce (5,021 total / 4,768 full-time employees at FY2025; 64.2% female, 58.6% U.S. racial/ethnic minority), OSHA Laboratory Safety (6 recordable injuries, 0.144 TRIR, 0.048 LTIR, 0.048 DART rate in FY2025), and Volunteer Hours (3,816 hours in FY2025); (8) Rebaselined GHG Inventory (227,208.94 tCO2e Total Scope 1–3 emissions and 0.066 tCO2e/test intensity in FY2025 across Scope 1 848.72 tCO2e, Scope 2 Market-Based 3,377.37 tCO2e / Location-Based 6,425.16 tCO2e, and Scope 3 222,982.85 tCO2e across all 7 categories, plus grid/renewable electricity, non-hazardous & biohazardous laboratory waste streams [0.168 lbs/test], and municipal water usage [4.08 gal/test]); and (9) 23 Federal Reserve FRED healthcare/laboratory macro series, 17 SEC XBRL peer series (EXAS, GH, MYGN, VCYT, CDNA, NEO, ILMN, DGX, LH), and Natera's DB Financial Statements & Product/Geographic Segments.
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; approximate bound disclosures such as '>60% market share' or '>1,000,000 cumulative patients' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Dữ liệu cập nhật 2026-11-02.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Diagnostic Test Volumes, Oncology MRD Adoption & Signatera ASP
Revenue by Payer Type, Sales Channel Mix, Prior-Period Cash Collection True-Ups & Gross Margin
Contract Liabilities (Deferred Revenue Roll-Forward) & Strategic Partnership RPO
Unconditional Purchase Commitments & Sequencing / Cloud Supply Obligations
CLIA Laboratory Facilities, Equipment PPE, Acquired Intangibles & Lease Maturity Schedule
Equity Awards, RSUs, Stock Options, Antidilutive Shares & Executive Compensation (DEF 14A)
- Unvested Restricted Stock Units (RSUs & PSUs) Outstanding (thousand shares)35 kỳ
- Stock Options Outstanding (thousand shares)35 kỳ
- Performance-Based Stock Award Compensation Expense ($M) ($M)30 kỳ
- Antidilutive Securities Excluded from Diluted EPS: RSUs & Performance Awards (thousand shares)22 kỳ
- CEO (PEO) Summary Compensation Table (SCT) Total Compensation ($) ($)6 kỳ
Global Workforce, Diversity, Laboratory Safety & Community
Environmental Sustainability — GHG Emissions (Scope 1, 2 & 3), Energy, Waste & Water
Diagnostic Laboratory Macro Benchmarks (FRED & Peers) & Core Financial Statements / Segments (DB)
- Census QSS Quarterly Revenue: U.S. Medical & Diagnostic Laboratories — NAICS 6215 ($M) ($M)46 kỳ
- BLS Producer Price Index (PPI): Medical Laboratories — NAICS 621511 (Jun 1994=100)140 kỳ
- BLS Employment: U.S. Ambulatory Health Care Services (thousand employees)140 kỳ
- Exact Sciences Corp. (EXAS) — GAAP Revenue ($M) ($M)11 kỳ
- Revenue by Offering Type — Product vs. Licensing and Other ($M, DB) ($M)50 kỳ
- Geographic Revenue: United States ($M, DB) ($M)49 kỳ
- Income Statement — Total Consolidated Revenue ($M, DB) ($M)50 kỳ
- Balance Sheet — Total Assets ($M, DB) ($M)46 kỳ
- Cash Flow Statement — Operating Cash Flow ($M, DB) ($M)48 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Natera
- Form 10-Q (2026-08-07) ↗
- Form 10-K (2026-02-27) ↗
- Natera 2025 Sustainability Report ↗
- Form 10-K (FY2025) ↗
- Form 8-K Ex 99.1 (2026-08-06) ↗
- Form 10-Q (2025-03-31) ↗
- Form 8-K Ex 99.1 (2026-02-26) ↗
- DEF 14A Proxy Statement (2026-04-23) ↗
- U.S. Census Bureau QSS / FRED (REV6215TAXABL144QNSA) ↗
- BLS / FRED (PCU621511621511) ↗
- BLS / FRED (CES6562100001) ↗
- Exact Sciences Corp. SEC 10-K (XBRL) ↗
See a number that looks wrong?